Polot	ed party transactions for the	pariad Oct 1 2022 to Mar 2	21 202	2														1
Relat	ed party transactions for the	e period Oct 1, 2022 to Mar 3	\$1, 202	.3							Additional disclosure of relat	ed party transaction	s - applicable o	nly in case the related party trar	nsaction relates to lo	ans, inter-corporate deposits, adv	vances or investments made or given by	the listed
	Details of the party (listed entity						Value of the			In case monies are due to either pa		entity/subsidiar	y. These details	s need to be disclosed only once	e, during the reportin	g period when such transaction v	vas undertaken.	1
	/subsidiary) entering into the transaction	Details of the	counterp	barty			related party	Remarks on	Value of transaction	as a result of the transaction	loans, inter-corporate dep			Deta	ils of the loans, inter	-corporate deposits, advances or	investments	
Sr No.				Relationship of the	Type of related party transaction	Details of other related party transaction	transaction as approved by	approval by	during the		Nature of indebtedness (loan,	/ Details of other		Nature (loan/ advance/			Purpose for which the funds will be	Notes
	Name PA	N Name	PAN c	counterparty with the listed entity or its subsidiary		,,	the audit	audit committee	reporting period	Opening balance Closing balance	e issuance of debt/ any other etc.)	indebtedness	Cost Tenure	intercorporate deposit/ investment)	Interest Rate (%)	Tenure Secured/unsecured	utilised by the ultimate recipient of funds (endusage)	
				,			committee							,				
1	Lupin Limited	Generic Health Pty Limited, Australia	wi	holly -Owned Subsidiary	Sale of goods or services		463.52	Approved	463.52	0.00 0.	DO							
2	Lupin Limited	Hormosan Pharma GmbH, Germany	14/8	holly -Owned Subsidiary	Sale of goods or services		66.79	Approved	66.78	0.00 0.	DO							
		Lupin Atlantis Holdings SA,																
3	Lupin Limited	Switzerland	Wi	holly -Owned Subsidiary	Sale of goods or services		567.64	Approved	567.64	0.00 0.	D0							
4	Lupin Limited	Lupin Healthcare (UK) Limited, UK	W	holly -Owned Subsidiary	Sale of goods or services		513.89	Approved	513.89	0.00 0.	DO							
5	Lupin Limited	Lupin Inc., USA	wi	holly -Owned Subsidiary	Sale of goods or services		3089.78	Approved	3089.78	0.00 0.	DO							
6	Lupin Limited	Lupin Pharma Canada Limited, Canada	w	holly -Owned Subsidiary	Sale of goods or services		252.28	Approved	252.28	0.00 0.	DO							
7	Lupin Limited	Lupin Pharmaceuticals, Inc., USA	Wi	holly -Owned Subsidiary	Sale of goods or services		8132.90	Approved	8132.90	0.00 0.	00							
8	Lupin Limited	Lupin Philippines, Inc., Philippines	W	holly -Owned Subsidiary	Sale of goods or services		52.43	Approved	52.43	0.00 0.	DO							
9	Lupin Limited	Lupin Research Inc., USA		holly -Owned Subsidiary	Sale of goods or services		57.08	Approved	57.08	0.00 0.	DO							
10	Lupin Limited	Medquimica Industria Farmaceutica LTDA, Brazil		holly -Owned Subsidiary	Sale of goods or services		422.92	Approved	422.92	0.00 0.	DO							
		Multicare Pharmaceuticals		bsidiary				Approved	67.44		DO							
	Lupin Limited	Philippines, Inc., Philippines			Sale of goods or services													
12	Lupin Limited	Novel Laboratories, Inc., USA Pharma Dynamics (Proprietary)	W	holly -Owned Subsidiary	Sale of goods or services		94.26	Approved	94.26	0.00 0.	DO							
13	Lupin Limited	Limited, South Africa	W	holly -Owned Subsidiary	Sale of goods or services		536.72	Approved	536.72	0.00 0.	DO							
14	Lupin Limited	Lupin Atlantis Holdings SA, Switzerland	wi	holly -Owned Subsidiary	Sale of goods or services		88.36	Approved	88.36	0.00 0.	DO							
	Lupin Limited	Lupin Inc., USA		holly -Owned Subsidiary	Sale of goods or services			Approved	13.59		DO							
16	Lupin Limited	Lupin Oncology Inc., USA	Su	bsidiary	Sale of goods or services		417.23	Approved	417.23	0.00 0.	DO							
17	Lupin Limited	Lupin Research Inc., USA	W	holly -Owned Subsidiary	Sale of goods or services		1.09	Approved	1.09	0.00 0.	DO							
	Lupin Limited	Lupin Inc., USA		holly -Owned Subsidiary	Sale of goods or services		827.10	Approved	827.10		DO							
19	Lupin Limited	Novel Laboratories, Inc., USA	Wi	holly -Owned Subsidiary	Sale of fixed assets		57.13	Approved	57.13	0.00 0.	DO							
20	Lupin Limited	Generic Health Pty Limited, Australia	wi	holly -Owned Subsidiary	Sale of goods or services		3.10	Approved	3.10	0.00 0.	DO							
21	Lupin Limited	Hormosan Pharma GmbH, Germany	wi	holly -Owned Subsidiary	Sale of goods or services		3.06	Approved	3.06	0.00 0.	DO							
	Lupin Limited	Lupin Europe GmbH, Germany	14/8	holly -Owned Subsidiary	Sale of goods or services		0.41	Approved	0.41	0.00 0.	DO							
		Lupin Atlantis Holdings SA,																
23	Lupin Limited	Switzerland	Wi	holly -Owned Subsidiary	Sale of goods or services		1.65	Approved	1.65	0.00 0.	DO							
24	Lupin Limited	Lupin Australia Pty Limited, Australia	W	holly -Owned Subsidiary	Sale of goods or services		0.25	Approved	0.25	0.00 0.	DO							
25	Lupin Limited	Lupin Digital Health Limited, India	wi	holly -Owned Subsidiary	Sale of goods or services		0.61	Approved	0.61	0.00 0.	DO							
26	Lupin Limited	Lupin Healthcare (UK) Limited, UK	w	holly -Owned Subsidiary	Sale of goods or services		2.53	Approved	2.53	0.00 0.	DO							
		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare																
27	Lupin Limited	Limited)		holly -Owned Subsidiary	Sale of goods or services		6.37	Approved	6.37	0.00 0.	DO							
28	Lupin Limited	Nanomi B.V., Netherlands	wi	holly -Owned Subsidiary	Sale of goods or services		2.09	Approved	2.09	0.00 0.	DO							
	Lupin Limited	Lupin Inc., USA		holly -Owned Subsidiary	Sale of goods or services			Approved	3.09		00							
30	Lupin Limited	Lupin Management, Inc., USA	W	holly -Owned Subsidiary	Sale of goods or services		1.20	Approved	1.20	0.00 0.	DO							
31	Lupin Limited	Lupin Oncology Inc., USA	Su	bsidiary	Sale of goods or services		0.07	Approved	0.07	0.00 0.	DO							
32	Lupin Limited	Lupin Pharma Canada Limited, Canada	wi	holly -Owned Subsidiary	Sale of goods or services		2.02	Approved	2.02	0.00 0.	DO							
	Lupin Limited	Lupin Pharmaceuticals, Inc., USA		holly -Owned Subsidiary	Sale of goods or services			Approved	23.44		DO							
34	Lupin Limited	Lupin Philippines, Inc., Philippines	W	holly -Owned Subsidiary	Sale of goods or services		0.71	Approved	0.71	0.00 0.	00							
35	Lupin Limited	Lupin Research Inc., USA Multicare Pharmaceuticals	W	holly -Owned Subsidiary	Sale of goods or services		2.29	Approved	2.29	0.00 0.	DO							
36	Lupin Limited	Philippines, Inc., Philippines	Su	bsidiary	Sale of goods or services		1.93	Approved	1.93	0.00 0.	DO							
37	Lupin Limited	Novel Laboratories, Inc., USA	wi	holly -Owned Subsidiary	Sale of goods or services		4.45	Approved	4.45	0.00 0.	DO							
		Pharma Dynamics (Proprietary)		holly -Owned Subsidiary	Sale of goods or services			Approved	8.38		00							
	Lupin Limited	Limited, South Africa Southern Cross Pharma Pty Ltd.,																
39	Lupin Limited	Australia Medquimica Industria Farmaceutica		holly -Owned Subsidiary	Sale of goods or services		0.49	Approved	0.49	0.00 0.	DO							
40	Lupin Limited	LTDA, Brazil	W	holly -Owned Subsidiary	Sale of goods or services		2.71	Approved	2.71	0.00 0.	DO							
41	Lupin Limited	Lupin Digital Health Limited, India	wi	holly -Owned Subsidiary	Any other transaction	Rent received	1.50	Approved	1.50	0.00 0.	DO							
			01	hers (Relatives of KMP and														
			En	tities in which the KMP and														
42	Lupin Limited	Polynova Industries Limited		latives of KMP have control significant influence)	Any other transaction	Rent received	0.81	Approved	0.81	0.00 0.	DO							
				·		Fees received against guarantee provided on												
43	Lupin Limited	Nanomi B.V., Netherlands	wi	holly -Owned Subsidiary	Any other transaction	their behalf	20.65	Approved	20.65	0.00 0.	DO							
						Fees received against guarantee provided on												
44	Lupin Limited	Lupin Pharmaceuticals, Inc., USA	W	holly -Owned Subsidiary		their behalf Fees received against	62.91	Approved	62.91	0.00 0.	DO							
		Medquimica Industria Farmaceutica				guarantee provided on												
45	Lupin Limited	LTDA, Brazil	Wi	holly -Owned Subsidiary	Any other transaction Purchase of goods or	their behalf	8.63	Approved	8.63	0.00 0.	DO							
46	Lupin Limited	Lupin Digital Health Limited, India	W	holly -Owned Subsidiary	services		0.04	Approved	0.04	0.00 0.	DO							
47	Lupin Limited	Lupin Research Inc., USA	wi	holly -Owned Subsidiary	Purchase of goods or services		178.34	Approved	178.34	0.00 0.	DO							

Polo	ted party transactions for the p	period Oct 1 2022 to Mar 3	31 7	2023																
Rela	tes party transactions for the p	20100 Oct 1, 2022 to war 3	, 2									Additional disclosure of relater							vances or investments made or given by	the listed
	Details of the party (listed entity				-		Value of the			In case monies are	due to either party	In case any financial indebted	entity/subsidiary	y. These detail make or give	s need to be disclosed only once					
	/subsidiary) entering into the transaction	Details of the	e coun	iterparty	Type of related party	Details of other related	related party	Remarks on	Value of transaction	as a result of the		loans, inter-corporate depo			Deta	ils of the loans, inter-	-corporat	te deposits, advances or	investments	
Sr No.	Name PAN	Name		Relationship of the counterparty with the listed	transaction	party transaction	transaction as approved by	approval by audit committee	during the reporting	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other	Details of other	Cost Tenure	Nature (loan/ advance/ intercorporate deposit/	Interest Rate (%)	Tonuro	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of	Notes
	Nume PAN	Name	1	entity or its subsidiary			the audit committee	addit committee	period	Opening balance	closing balance	etc.)	indebtedness	cust renure	investment)	Interest Rate (%)	Tenure	secured/ unsecured	funds (endusage)	
				Others (Relatives of KMP and Entities in which the KMP and																
48	Lupin Limited	S. N. Pharma		Relatives of KMP have control or significant influence)	Purchase of goods or services		49.03	Approved	49.03	0.00	0.00									
	capit childed	5.14.11101110			Jervices		45.05	Approved	45.05	0.00	0.00									
				Others (Relatives of KMP and Entities in which the KMP and																
40	Lupin Limited	Shuban Prints		Relatives of KMP have control or significant influence)	Purchase of goods or services		21 50	Approved	31.58	0.00	0.00									
					Purchase of goods or															
50	Lupin Limited	Hormosan Pharma GmbH, Germany Laboratorios Grin, S.A. de C.V.,	-	Wholly -Owned Subsidiary	services Purchase of goods or		17.58	Approved	17.58	0.00	0.00									
51	Lupin Limited	Mexico Lupin Atlantis Holdings SA,		Wholly -Owned Subsidiary	services Purchase of goods or		9.75	Approved	9.75	0.00	0.00									
52		Switzerland		Wholly -Owned Subsidiary	services		23.27	Approved	23.27	0.00	0.00									
53	Lupin Limited	Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Purchase of goods or services		73.05	Approved	73.05	0.00	0.00									
		Lupin Diagnostics Limited, India																		
54	Lupin Limited	(formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary	Purchase of goods or services		6.02	Approved	6.02	0.00	0.00									
		Lupin Inc., USA			Purchase of goods or services			Approved	67.09											
					Purchase of goods or															
	Lupin Limited	Lupin Management, Inc., USA		Wholly -Owned Subsidiary	services Purchase of goods or			Approved	323.94	0.00										
57	Lupin Limited	Lupin Pharmaceuticals, Inc., USA	-	Wholly -Owned Subsidiary	services		38.38	Approved	38.38	0.00	0.00									
				Others (Relatives of KMP and																
				Entities in which the KMP and Relatives of KMP have control	Purchase of goods or															
58	Lupin Limited	S. N. Pharma			services		15.16	Approved	15.16	0.00	0.00									
				Others (Relatives of KMP and																
				Entities in which the KMP and Relatives of KMP have control	Purchase of goods or															
59	Lupin Limited	TeamLease Services Limited			services		24.53	Approved	24.53	0.00	0.00									
60	Lupin Limited	Novel Laboratories, Inc., USA		Wholly -Owned Subsidiary	Purchase of fixed assets		48.76	Approved	48.76	0.00	0.00									
				Others (Relatives of KMP and																
				Entities in which the KMP and																
61	Lupin Limited	Zyma Properties Pvt. Limited		Relatives of KMP have control or significant influence)	Any other transaction	Rent Paid	5.51	Approved	5.51	0.00	0.00									
				Others (Relatives of KMP and																
				Entities in which the KMP and																
62	Lupin Limited	Lupin Human Welfare and Research Foundation		Relatives of KMP have control or significant influence)	Any other transaction	Donation	260.91	Approved	260.91	0.00	0.00									
				Others (Relatives of KMP and																
				Entities in which the KMP and																
63	Lupin Limited	Mata Shree Gomati Devi Jan Seva Nidhi		Relatives of KMP have control or significant influence)	Any other transaction	Donation	9.00	Approved	9.00	0.00	0.00									
						Expenses incurred on														
						our behalf reimbursed &														
64	Lupin Limited	Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction	Other Reimbursements	2.31	Approved	2.31	0.00	0.00									
						Expenses incurred on our behalf reimbursed &														
65	Lupin Limited	Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary			8.76	Approved	8.76	0.00	0.00									
						Expenses incurred on														
66	Lupin Limited	Lupin Europe GmbH, Germany		Wholly -Owned Subsidiary		our behalf reimbursed & Other Reimbursements	17.33	Approved	17.33	0.00	0.00									
						Expenses incurred on														
		Lupin Atlantis Holdings SA,				our behalf reimbursed &														
67	Lupin Limited	Switzerland	-	Wholly -Owned Subsidiary	Any other transaction	Uther Reimbursements	0.43	Approved	0.43	0.00	0.00									<u> </u>
						Expenses incurred on our behalf reimbursed &														
68	Lupin Limited	Lupin Australia Pty Limited, Australia		Wholly -Owned Subsidiary			21.27	Approved	21.27	0.00	0.00									
						Expenses incurred on														
	Lupin Limited	Lupin Digital Health Limited, India		Wholly -Owned Subsidiary		our behalf reimbursed & Other Reimbursements		Approved	0.49	0.00	0.00									
09	Eupin Eimiteu			whony -Owned Subsidiary			0.49	Approveu	0.49	0.00	0.00									
		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare				Expenses incurred on our behalf reimbursed &														
70	Lupin Limited	Limited)		Wholly -Owned Subsidiary	Any other transaction	Other Reimbursements	1.41	Approved	1.41	0.00	0.00									
						Expenses incurred on														
71	Lupin Limited	Lupin Inc., USA		Wholly -Owned Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements	180.85	Approved	180.85	0.00	0.00									
						Expenses incurred on														
				Entity having significant		our behalf reimbursed &														
72	Lupin Limited	Lupin Investments Pvt. Limited	-	influence over the company			0.00	Approved	0.00	0.00	0.00									
						Expenses incurred on														
73	Lupin Limited	Lupin Management, Inc., USA		Wholly -Owned Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements	2.33	Approved	2.33	0.00	0.00									
						Expenses incurred on														
	Lunia Limited	Lupin Pharma Canada Limited, Canada		Whethe Owned Schutzer		our behalf reimbursed &		Annual I		0.00	0.00									
74	Lupin Limited	Canada		Wholly -Owned Subsidiary	Any other transaction	Other Reimbursements	16.04	Approved	16.04	U.00	U.00									
						Expenses incurred on our behalf reimbursed &														
75	Lupin Limited	Lupin Pharmaceuticals, Inc., USA		Wholly -Owned Subsidiary		Other Reimbursements	558.30	Approved	558.30	0.00	0.00									

Rela	ted party t	ransactions for t	he pe	eriod Oct 1, 2022 to Mar	31, 2	023																
														Additional disclosure of relater			ble only in case the related party tran etails need to be disclosed only once				ances or investments made or given by vas undertaken.	the listed
		of the party (listed entity entering into the transact		Details of th	e count	terparty			Value of the related party		Value of	In case monies are as a result of t	due to either party	In case any financial indebted loans, inter-corporate depo	ness is incurred to	make or gi	Deta			e deposits, advances or		
Sr No.		entering into the transact	LIOII			Relationship of the	Type of related party	Details of other related	transaction as	Remarks on approval by	transaction during the	as a result of th		Nature of indebtedness (loan/		ivestillents	Nature (loan/ advance/				Purpose for which the funds will be	Notes
		Name	PAN	Name	PAN		transaction	party transaction	approved by the audit	audit committee	reporting period	Opening balance	Closing balance	issuance of debt/ any other etc.)	Details of other indebtedness	Cost Ten		Interest Rate (%)	Tenure	Secured/ unsecured	utilised by the ultimate recipient of funds (endusage)	
					_	entity or its subsidiary			committee		penou			etc.)			investment)				runds (endusage)	
				Pharma Dynamics (Proprietary)				Expenses incurred on our behalf reimbursed &														
76	Lupin Limited			Limited, South Africa		Wholly -Owned Subsidiary	Any other transaction	Other Reimbursements		Approved	0.01	0.00	0.00									
						Others (Relatives of KMP and																
						Entities in which the KMP and Relatives of KMP have control		Expenses incurred on our behalf reimbursed &														
77	Lupin Limited		9	5. N. Pharma	_	or significant influence)	Any other transaction	Other Reimbursements	2.30	Approved	2.30	0.00	0.00									
								Expenses incurred on														
78	Lupin Limited			Generic Health Pty Limited, Australia	1	Wholly -Owned Subsidiary	Any other transaction	their behalf recovered	14.56	Approved	14.56	0.00	0.00									
79	Lupin Limited		,	Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	8.38	Approved	8.38	0.00	0.00									
				Laboratorios Grin, S.A. de C.V.,				Expenses incurred on														
80	Lupin Limited			Mexico		Wholly -Owned Subsidiary	Any other transaction	their behalf recovered	7.13	Approved	7.13	0.00	0.00									
				Lupin Atlantis Holdings SA,				Expenses incurred on														
81	Lupin Limited		5	Switzerland		Wholly -Owned Subsidiary	Any other transaction		12.57	Approved	12.57	0.00	0.00									
82	Lupin Limited			Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	1.82	Approved	1.82	0.00	0.00									
								Expenses incurred on														
83	Lupin Limited			Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Any other transaction	their behalf recovered	11.73	Approved	11.73	0.00	0.00									
			(Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare	2			Expenses incurred on														
84	Lupin Limited		-	Limited)	-	Wholly -Owned Subsidiary	Any other transaction		6.24	Approved	6.24	0.00	0.00									
85	Lupin Limited		,	Nanomi B.V., Netherlands		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	2.48	Approved	2.48	0.00	0.00									
								Expenses incurred on														
86	Lupin Limited			Lupin Inc., USA		Wholly -Owned Subsidiary	Any other transaction		22.25	Approved	22.25	0.00	0.00									
								Expenses incurred on														
87	Lupin Limited			Lupin Management, Inc., USA		Wholly -Owned Subsidiary	Any other transaction	their behalf recovered	51.02	Approved	51.02	0.00	0.00									
88	Lupin Limited			Lupin Pharma Canada Limited, Canada		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	3.67	Approved	3.67	0.00	0.00									
								Expenses incurred on														
89	Lupin Limited			Lupin Pharmaceuticals, Inc., USA		Wholly -Owned Subsidiary	Any other transaction		133.89	Approved	133.89	0.00	0.00									
								Expenses incurred on														
90	Lupin Limited			Lupin Philippines, Inc., Philippines	-	Wholly -Owned Subsidiary	Any other transaction	their behalf recovered	0.01	Approved	0.01	0.00	0.00									
91	Lupin Limited			Lupin Research Inc., USA		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	12.88	Approved	12.88	0.00	0.00									
				Medquimica Industria Farmaceutica			,	Expenses incurred on														
92	Lupin Limited			LTDA, Brazil		Wholly -Owned Subsidiary	Any other transaction		8.69	Approved	8.69	0.00	0.00									
				Multicare Pharmaceuticals				Expenses incurred on														
93	Lupin Limited		1	Philippines, Inc., Philippines	-	Subsidiary	Any other transaction	their behalf recovered	8.17	Approved	8.17	0.00	0.00									
94	Lupin Limited			Novel Laboratories, Inc., USA		Wholly -Owned Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	27.92	Approved	27.92	0.00	0.00									
				Pharma Dynamics (Proprietary)			,	Expenses incurred on														
95	Lupin Limited			Limited, South Africa		Wholly -Owned Subsidiary	Any other transaction		7.26	Approved	7.26	0.00	0.00									
						Others (Relatives of KMP and																
1						Entities in which the KMP and Relatives of KMP have control		Expenses incurred on														
96	Lupin Limited		-	Polynova Industries Limited	_	or significant influence)	Any other transaction	their behalf recovered	0.91	Approved	0.91	0.00	0.00									
97	Lupin Limited		-	Mr. R. V. Satam	_	Key Management Personnel	Remuneration		4.42	Approved	4.42	0.00	0.00									
98	Lupin Limited			Mr. Ramesh Swaminathan		Key Management Personnel	Remuneration		43.36	Approved	43.36	0.00	0.00									
99	Lupin Limited			Mr. Nilesh D. Gupta		Key Management Personnel	Remuneration		23.07	Approved	23.07	0.00	0.00									
				Ms. Christine Mundkur (Ceased to b	e			Commission / Sitting														
100	Lupin Limited		á	a Director w.e.f. January 1, 2023)	_	Independent Director	Any other transaction		6.29	Approved	6.29	0.00	0.00									
104	Lupin Limited			Dr. Kamal K. Sharma (Ceased to be a Director w.e.f. October 14, 2022)		Non- Executive Directors	Any other transaction	Commission / Sitting		Approved		0.00	0.00									
								Commission / Sitting		Approved	8.72											
	Lupin Limited			Mr. Jean-Luc Belingard	-		Any other transaction	Commission / Sitting		Approved	1.37											
103	Lupin Limited			Mr. K. B. S. Anand	-	Independent Director	Any other transaction	Fees Commission / Sitting	1.49	Approved	1.49	0.00	0.00									
104	Lupin Limited		-	Mr. Mark D. Mcdade	_	Independent Director	Any other transaction		1.39	Approved	1.39	0.00	0.00									
105	Lupin Limited			Mrs. Manju D. Gupta		Non- Executive Directors	Any other transaction	Fees	1.37	Approved	1.37	0.00	0.00									
106	Lupin Limited			Dr. Punita Kumar-Sinha		Independent Director	Any other transaction	Commission / Sitting Fees	1.53	Approved	1.53	0.00	0.00									
1				Dr. Kamal K. Sharma (Ceased to be a				Value of Perquisites]
107	Lupin Limited			Director w.e.f. October 14, 2022)	-		Any other transaction Purchase of goods or		0.39	Approved	0.39	0.00	0.00									
108	Lupin Limited		-	Lupin Research Inc., USA		Wholly -Owned Subsidiary	services		181.27	Approved	181.27	0.00	0.00									
109	Lupin Limited		<u> </u>	Novel Laboratories, Inc., USA			Purchase of goods or services		261.92	Approved	261.92	0.00	0.00									
110	Lupin Limited			Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	280.53	374.33									
	Lupin Limited		,	Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	0.00	40.02									
				Lupin Atlantis Holdings SA, Switzerland							0.00											
112	Lupin Limited			owitzefland	1	Wholly -Owned Subsidiary	Any other transaction	neceivables	0.00	Approved	U.00	405.27	371.41									

Rela	ted party transactions for the p	eriod Oct 1, 2022 to Mar 3	31, 20	023																
												Additional disclosure of relate			inly in case the related party tra s need to be disclosed only once				vances or investments made or given by vas undertaken.	the listed
	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the	e counte	erparty			Value of the related party		Value of	In case monies are of as a result of th		In case any financial indebted loans, inter-corporate dept	dness is incurred to	make or give				te deposits, advances or		
Sr No			T	Relationship of the	Type of related party	Details of other related	transaction as	Remarks on approval by	transaction during the	as a result of th		Nature of indebtedness (loan/		ivestments	Nature (loan/ advance/		<u> </u>	1	Purpose for which the funds will be	Notes
	Name PAN	Name	PAN	counterparty with the listed	transaction	party transaction	approved by the audit	audit committee	reporting	Opening balance	Closing balance	issuance of debt/ any other	Details of other indebtedness	Cost Tenure	intercorporate deposit/	Interest Rate (%)	Tenure	Secured/ unsecured	utilised by the ultimate recipient of	
				entity or its subsidiary			committee		period			etc.)			investment)				funds (endusage)	
	Lupin Limited	Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction			Approved	0.00	657.32	616.41									
		Lupin Inc., USA Lupin Oncology Inc., USA		Subsidiary	Any other transaction Any other transaction			Approved Approved	0.00	1750.60 1794.62	1876.79 2228.82									
116		Lupin Pharma Canada Limited, Canada		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	331.00	262.89									
		Lupin Pharmaceuticals, Inc., USA			Any other transaction		0.00	Approved	0.00		9257.37									
118	Lupin Limited	Lupin Philippines, Inc., Philippines		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	238.82	263.62									
119		Lupin Research Inc., USA Medouimica Industria Farmaceutica		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	49.09	57.19									
120		LTDA, Brazil Multicare Pharmaceuticals		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	268.43	289.11									
	Lupin Limited	Philippines, Inc., Philippines		Subsidiary	Any other transaction	Receivables		Approved	0.00	71.22	0.00									
122		Novel Laboratories, Inc., USA Pharma Dynamics (Proprietary)		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	34.17	95.25									
123	Lupin Limited	Limited, South Africa		Wholly -Owned Subsidiary	Any other transaction	Receivables	0.00	Approved	0.00	174.34	306.92									
124	Lupin Limited	Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	1.23	1.84									
125	Lupin Limited	Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	1.36	1.57									
126	5 Lupin Limited	Lupin Europe GmbH, Germany Lupin Atlantis Holdings SA,		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.18	0.23									
127		Switzerland		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.79	0.81						-			
128	Lupin Limited	Lupin Australia Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.10	0.15									
129	Lupin Limited	Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.14	0.37									
	Lupin Limited	Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary	Any other transaction	Income Receivable		Approved	0.00	3.31	2.22									
130		Lupin Diagnostics Limited, India			any other a macholi		0.00	pp:0400	0.00	3.31	2.22									
	Lupin Limited	(formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary		Income Receivable		Approved	0.00	3.82	2.94									
132	Lupin Limited	Nanomi B.V., Netherlands Lupin Inc., USA			Any other transaction Any other transaction			Approved Approved	0.00		22.66						-			
134	Lupin Limited	Lupin Management, Inc., USA		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	3.02	0.37									
		Lupin Oncology Inc., USA Lupin Pharma Canada Limited,		Subsidiary	Any other transaction			Approved	0.00		0.16									
		Canada Lupin Pharmaceuticals, Inc., USA		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction Any other transaction	Income Receivable Income Receivable		Approved Approved	0.00	1.03 29.99	1.14 44.31									
	Lupin Limited	Lupin Philippines, Inc., Philippines		Wholly -Owned Subsidiary	Any other transaction	Jacomo Dossiuskie		Approved	0.00	0.27	0.71									
	Lupin Limited	Lupin Research Inc., USA			Any other transaction		0.00	Approved	0.00		1.10									
140		Medquimica Industria Farmaceutica LTDA, Brazil		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	4.33	5.45									
141		Multicare Pharmaceuticals Philippines, Inc., Philippines		Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.86	0.90									
	Lupin Limited	Novel Laboratories, Inc., USA			Any other transaction		0.00	Approved	0.00		2.49									
143	Lupin Limited	Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	4.14	3.91									
144		Southern Cross Pharma Pty Ltd., Australia		Wholly -Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved	0.00	0.35	0.37									
	Lupin Limited	Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary		Expenses receivable		Approved	0.00	1.62	3.25									
146	5 Lupin Limited	Hormosan Pharma GmbH, Germany Laboratorios Grin, S.A. de C.V.,		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable		Approved	0.00	2.77	4.12									
147	Lupin Limited	Mexico Lupin Atlantis Holdings SA,		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable	0.00	Approved	0.00	1.27	3.79									
148		Switzerland		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable	0.00	Approved	0.00	7.04	3.23									
149	Lupin Limited	Lupin Digital Health Limited, India		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable	0.00	Approved	0.00	2.72	2.29									
	Lupin Limited	Lupin Healthcare (UK) Limited, UK		Wholly -Owned Subsidiary		Expenses receivable		Approved	0.00	3.49	6.42									
		Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare		, ee. subsidiary	, enter a unaccion		0.00		0.00	5.43	0.42									
	Lupin Limited	Limited)		Wholly -Owned Subsidiary	Any other transaction			Approved	0.00	0.69	4.37									
	Lupin Limited	Nanomi B.V., Netherlands Lupin Inc., USA		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction Any other transaction	Expenses receivable Expenses receivable		Approved Approved	0.00		2.47 15.60									
	Lupin Limited	Lupin Management, Inc., USA Lupin Pharma Canada Limited,			Any other transaction			Approved	0.00		26.97									
	Lupin Limited	Canada			Any other transaction			Approved	0.00	1.24	1.99									
156	Lupin Limited	Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction Any other transaction	Expenses receivable Expenses receivable		Approved Approved	0.00	16.61 3.68	98.73 6.91									
158		Medquimica Industria Farmaceutica LTDA, Brazil		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable	0.00	Approved	0.00	2.96	4.60									
		Multicare Pharmaceuticals Philippines, Inc., Philippines		Subsidiary	Any other transaction			Approved	0.00	3.46	3.64									
160) Lupin Limited	Novel Laboratories, Inc., USA			Any other transaction Any other transaction		0.00	Approved	0.00		3.64									
161	Lupin Limited	Pharma Dynamics (Proprietary) Limited, South Africa		Wholly -Owned Subsidiary	Any other transaction	Expenses receivable	0.00	Approved	0.00	0.54	3.57									
		Lupin Atlantis Holdings SA, Switzerland		Wholly -Owned Subsidiary	Investment			Approved	0.00	32805.56	32805.56									
163	Lupin Limited	Lupin Australia Pty Limited, Australia Lupin Biologics Limited, India		Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Investment Investment			Approved Approved	0.00	33.32 1.50	33.32 1.50									
165	Lupin Limited	Lupin Digital Health Limited, India	ļĪ	Wholly -Owned Subsidiary	Investment		302.90	Approved	302.90	697.10	1000.00]
10.		Lupin Diagnostics Limited, India		,						057.20										
	Lupin Limited	(formerly known as Lupin Healthcare Limited)		Wholly -Owned Subsidiary	Investment			Approved	500.00		1581.67									
		Nanomi B.V., Netherlands Lupin Oncology Inc., USA		Wholly -Owned Subsidiary Subsidiary	Investment Investment		7008.90	Approved Approved	7008.90		57894.12 1127.85						-			
		Lupin Pharmaceuticals, Inc., USA			Investment			Approved	0.00		13.79									
				Others (Relatives of KMP and																
				Entities in which the KMP and Relatives of KMP have control																
170	Lupin Limited	Zyma Properties Pvt. Limited		or significant influence)	Inter-corporate deposit		0.00	Approved	0.00	7.40	7.40									<u> </u>
171	Lupin Limited	Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	3.58	2.74									
172	Lupin Limited	Hormosan Pharma GmbH, Germany		Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	18.47	16.41									

Related party transactions for the	e period Oct 1, 2022 to Mar 31	L, 2023																
										Additional disclosure of relate			inly in case the related party trans s need to be disclosed only once				vances or investments made or given by	y the listed
Details of the party (listed entity	Details of the o	ounterparty			Value of the		Value of			In case any financial indebted	dness is incurred to	make or give				e deposits, advances or		1
/subsidiary) entering into the transaction	n		Type of related party	Details of other related	related party transaction as	Remarks on approval by	transaction during the	as a result of the	transaction	loans, inter-corporate depo	osits, advances or i	nvestments				[1	Notes
Name PA	N Name I	PAN counterparty with the listed	transaction	party transaction	approved by the audit	audit committee	reporting	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other	Details of other indebtedness	Cost Tenure		Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of	Notes
	Laboratorios Grin, S.A. de C.V.	entity or its subsidiary			committee		period			etc.)	indebicaness		investment)				funds (endusage)	
173 Lupin Limited	Mexico	Wholly -Owned Subsidiary	Any other transaction			Approved	0.00		8.74									
174 Lupin Limited	Lupin Europe GmbH, Germany Lupin Atlantis Holdings SA,	Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	2.31	17.93									
175 Lupin Limited	Switzerland	Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	14.79	8.20									
176 Lupin Limited	Lupin Digital Health Limited, India	Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	1.23	0.50									
177 Lupin Limited	Lupin Healthcare (UK) Limited, UK	Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	95.91	97.32									
	Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare																	
178 Lupin Limited 179 Lupin Limited	Limited) Lupin Management, Inc., USA	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction Any other transaction		0.00	Approved Approved	0.00		1.07 213.88									
180 Lupin Limited	Lupin Pharma Canada Limited, Canada	Wholly -Owned Subsidiary	Any other transaction	Pavables		Approved	0.00	48.77	65.87									
181 Lupin Limited	Lupin Pharmaceuticals, Inc., USA	Wholly -Owned Subsidiary	Any other transaction	Payables	0.00	Approved	0.00	162.84	184.79									
182 Lupin Limited	Lupin Research Inc., USA Medquimica Industria Farmaceutica	Wholly -Owned Subsidiary	Any other transaction			Approved	0.00		918.78									
183 Lupin Limited 184 Lupin Limited	LTDA, Brazil Novel Laboratories, Inc., USA	Wholly -Owned Subsidiary Wholly -Owned Subsidiary	Any other transaction Any other transaction			Approved Approved	0.00		0.00									
185 Lupin Limited	Pharma Dynamics (Proprietary) Limited, South Africa	Wholly -Owned Subsidiary	Any other transaction	Pavables	0.00	Approved	0.00	3.31	1.32									
		Others (Relatives of KMP and	., ener a unacción	,	0.00		0.00	5.51	1.52									
		Entities in which the KMP and																
186 Lupin Limited	S. N. Pharma	Relatives of KMP have control or significant influence)	Any other transaction	Payables	0.00	Approved	0.00	2.51	11.31									
		Others (Relatives of KMP and																
		Entities in which the KMP and Relatives of KMP have control																
187 Lupin Limited	Shuban Prints	or significant influence)	Any other transaction	Payables	0.00	Approved	0.00	0.90	1.40									
		Others (Relatives of KMP and																
		Entities in which the KMP and Relatives of KMP have control																
188 Lupin Limited	TeamLease Services Limited	or significant influence)	Any other transaction	Payables	0.00	Approved	0.00	0.02	0.02									
189 Lupin Limited	Lupin Australia Pty Limited, Australia	Wholly -Owned Subsidiary		Expns Payable	0.00	Approved	0.00		9.87									
190 Lupin Limited	Lupin Inc., USA	Wholly -Owned Subsidiary	Any other transaction			Approved	0.00		217.71									
191 Lupin Limited	Lupin Philippines, Inc., Philippines	Wholly -Owned Subsidiary	Any other transaction	Expenses payable	0.00	Approved	0.00	0.91	0.92									
		Others (Relatives of KMP and Entities in which the KMP and																
		Relatives of KMP have control																
192 Lupin Limited	Polynova Industries Limited	or significant influence)	Inter-corporate deposit			Approved	0.00	0.10	0.10									
		Others (Relatives of KMP and Entities in which the KMP and																
193 Lupin Limited	S. N. Pharma	Relatives of KMP have control or significant influence)	Advance		0.00	Approved	0.00	20.00	16.67									
195 Copin Chintee	J. N. Fliatilia		Advance		0.00	Аррготеа	0.00	20.00	10.07									
		Others (Relatives of KMP and Entities in which the KMP and																
194 Lupin Limited	Shuban Prints	Relatives of KMP have control or significant influence)	Advance		0.00	Approved	0.00	20.00	18.33									
				Corporate guarantees														
				issued by the Company to the bankers of														
195 Lupin Limited	Lupin Healthcare (UK) Limited, UK	Wholly -Owned Subsidiary	Any other transaction	subsidiary company	59.02	Approved	59.02	59.02	0.00									
				Corporate guarantees														
				issued by the Company to the bankers of														
196 Lupin Limited	Lupin Pharmaceuticals, Inc., USA	Wholly -Owned Subsidiary	Any other transaction	subsidiary company		Approved	0.00	35080.03	33484.28									
				Corporate guarantees issued by the Company														
107 Locia Marinel	Medquimica Industria Farmaceutica LTDA, Brazil		Any other transaction	to the bankers of				2055 50	4044.07									
197 Lupin Limited	LIDA, Brazil	Wholly -Owned Subsidiary	Any other transaction			Approved	0.00	2056.50	1811.07									
				Guarantees issued by the Company on behalf														
				of subsidiary companies for contractual														
198 Lupin Limited	Nanomi B.V., Netherlands Southern Cross Pharma Pty Ltd.,	Wholly -Owned Subsidiary	Any other transaction	obligations		Approved	0.00	5075.07	5502.10									
199 Generic Health Pty Limited, Australia	Australia	Fellow Subsidiary	Investment			Not Applicable	0.00	1665.95	1665.95									
200 Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia	Fellow Subsidiary	Purchase of goods or services			Not Applicable	0.05	0.00	0.00									
201 Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Ltd., Australia	Fellow Subsidiary	Purchase of goods or services			Not Applicable	34.73	0.00	0.00									
202 Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia	Fellow Subsidiary	Any other transaction	Reimbursement		Not Applicable	0.15	0.00	0.00									
203 Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Ltd., Australia	Fellow Subsidiary	Any other transaction			Not Applicable	2.42		0.00									
204 Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia Southern Cross Pharma Pty Ltd.,	Fellow Subsidiary	Loan			Not Applicable	0.00		10.45									
205 Generic Health Pty Limited, Australia	Australia	Fellow Subsidiary	Loan			Not Applicable	0.00	63.38	7.63									
206 Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia	Fellow Subsidiary	Any other transaction	Trade Receivable		Not Applicable	0.00	0.12	0.12									<u> </u>
207 Generic Health Pty Limited, Australia	Lupin Australia Pty Limited, Australia	Fellow Subsidiary	Any other transaction	Trade Payable		Not Applicable	0.00	0.29	0.09									
208 Generic Health Pty Limited, Australia	Southern Cross Pharma Pty Ltd., Australia	Fellow Subsidiary	Any other transaction	Trade Payable		Not Applicable	0.00	14.47	8.83									
209 Hormosan Pharma GmbH, Germany	Lupin Europe GmbH, Germany	Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	0.00	10.30									
210 Hormosan Pharma GmbH, Germany	Nanomi B.V., Netherlands	Fellow Subsidiary	Any other transaction			Not Applicable	0.00		0.00									
211 Hormosan Pharma GmbH, Germany	Lupin Europe GmbH, Germany	Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	0.00	5.35	1					1		1	1

Rela	ted party transactions for the	period Oct 1, 2022 to Mar	31, 20	023																
													entity/subsidiar	y. These d	letails need to be disclosed only o				ances or investments made or given by vas undertaken.	y the listed
	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the	e count	erparty			Value of the related party	D	Value of	In case monies are as a result of t	due to either party he transaction	In case any financial indebted loans, inter-corporate depo				etails of the loans, inte	er-corpora	te deposits, advances or	investments	
Sr No				Relationship of the	Type of related party transaction	Details of other related party transaction	transaction as approved by	Remarks on approval by	transaction during the			Nature of indebtedness (loan/	Details of other		Nature (loan/ advance/				Purpose for which the funds will be	Notes
	Name PA	N Name	PAN	counterparty with the listed entity or its subsidiary	d'ansaction	purty transaction	the audit committee	audit committee	reporting period	Opening balance	Closing balance	issuance of debt/ any other etc.)	indebtedness	Cost Te	nure intercorporate deposit, investment)	Interest Rate (%) Tenure	Secured/ unsecured	utilised by the ultimate recipient of funds (endusage)	
							committee										-			
	Hormosan Pharma GmbH, Germany	Lupin Europe GmbH, Germany		Fellow Subsidiary	Interest received			Not Applicable	1.49	0.00				-			-			
213	Hormosan Pharma GmbH, Germany	Lupin Europe GmbH, Germany		Fellow Subsidiary	Any other transaction Purchase of goods or	Other Income		Not Applicable	19.63	0.00	0.00			-		-	-			
214	Hormosan Pharma GmbH, Germany	Nanomi B.V., Netherlands		Fellow Subsidiary	services			Not Applicable	0.01	0.00	0.00			_			_			
219	Hormosan Pharma GmbH, Germany	Lupin Europe GmbH, Germany		Fellow Subsidiary	Loan			Not Applicable	0.00	126.33	44.72			_	Loan	0.75	% 2 yrs	Unsecured	Business Purpose	
						Expenses incurred on														
216	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	13.38	0.00	0.00									
						Expenses incurred on														
217	Lupin Atlantis Holdings SA, Switzerland	Lupin Europe GmbH, Germany		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	23.73	0.00	0.00									
						Expenses incurred on														
210	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	110.18	0.00	0.00									
	Swittendid	nonnosan manna amori, acimariy		Tenow Subsidiary	any other duringedon			Not Applicable	110.10	0.00	0.00									
	Lupin Atlantis Holdings SA,	Lupin Pharma Canada Limited,				Expenses incurred on our behalf reimbursed &														
219	Switzerland	Canada		Fellow Subsidiary	Any other transaction			Not Applicable	196.21	0.00	0.00									
	Lupin Atlantis Holdings SA,					Expenses incurred on our behalf reimbursed &														
220	Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Any other transaction	Other Reimbursements		Not Applicable	17.92	0.00	0.00			_						
1	Lupin Atlantis Holdings SA.					Expenses incurred on our behalf reimbursed &														
22:	Switzerland	Lupin Research Inc., USA		Fellow Subsidiary	Any other transaction	Other Reimbursements		Not Applicable	17.85	0.00	0.00									
	Lunia Aslandia Habilia CA					Expenses incurred on														
222	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	11.54	0.00	0.00									
						Expenses incurred on														
223	Lupin Atlantis Holdings SA, Switzerland	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	5.75	0.00	0.00									
						Expenses incurred on														
22	Lupin Atlantis Holdings SA, Switzerland	Lupin Management, Inc., USA		Fellow Subsidiary	Any other transaction	our behalf reimbursed & Other Reimbursements		Not Applicable	4.45	0.00	0.00									
226	Switzenand	Lupin Management, Inc., USA		renow subsidiary	Any other transaction			NOT Applicable	4.43	0.00	0.00									
	Lupin Atlantis Holdings SA,					Expenses incurred on our behalf reimbursed &														
225	Switzerland	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	Other Reimbursements		Not Applicable	2.12	0.00	0.00			-			_			
	Lupin Atlantis Holdings SA,					Expenses incurred on our behalf reimbursed &														
226	Switzerland Lupin Atlantis Holdings SA,	YL Biologics Ltd., Japan		Jointly Controlled Entity	Any other transaction	Other Reimbursements		Not Applicable	2.86	0.00	0.00			_						
22	Switzerland Lupin Atlantis Holdings SA,	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	64.97	32.99			_						
228	Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	63.88	162.27									
	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	1.55	2.26									
	Lupin Atlantis Holdings SA, Switzerland	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	1219.53	993.33									
23:	Lupin Atlantis Holdings SA, Switzerland	Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	1.54	1.65									
233	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	0.00	0.43									
	Lupin Atlantis Holdings SA, Switzerland	Lupin Management, Inc., USA		Fellow Subsidiary		Receivables		Not Applicable	0.00	0.00										
	Lupin Atlantis Holdings SA, Switzerland	Medquimica Industria Farmaceutica LTDA, Brazil		Wholly -Owned Subsidiary	Any other transaction			Not Applicable	0.00	0.00										
	Lupin Atlantis Holdings SA,																			
	Switzerland Lupin Atlantis Holdings SA,	Generic Health Pty Limited, Australia		Wholly -Owned Subsidiary	Any other transaction			Not Applicable	0.00	0.00							-			
236	Switzerland Lupin Atlantis Holdings SA,	YL Biologics Ltd., Japan Laboratorios Grin, S.A. de C.V.,		Jointly Controlled Entity	Any other transaction	Receivables		Not Applicable	0.00	20.40	14.83									
23	Switzerland Lupin Atlantis Holdings SA,	Mexico		Fellow Subsidiary	Investment			Not Applicable	0.00	6149.55	6149.55						_			
238	Switzerland Lupin Atlantis Holdings SA,	Lupin Europe GmbH, Germany		Fellow Subsidiary	Investment			Not Applicable	0.00	40.95	172.62									\vdash
	Switzerland Lupin Atlantis Holdings SA,	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Investment			Not Applicable	0.00	279.75	279.75									
	Switzerland	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Investment			Not Applicable	0.00	250.76	250.76						_			
24:	Lupin Atlantis Holdings SA, Switzerland	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Investment			Not Applicable	0.00	4170.25	4170.25									
24	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary	Investment			Not Applicable	231.00	22776.60	23007.60									
	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	62.01										
	Lupin Atlantis Holdings SA, Switzerland	Lupin Europe GmbH, Germany		Fellow Subsidiary	Any other transaction			Not Applicable	0.00	4.99										
	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Any other transaction				0.00	13.08										
	Lupin Atlantis Holdings SA,							Not Applicable												
	Switzerland Lupin Atlantis Holdings SA,	Lupin Inc., USA		Fellow Subsidiary	Any other transaction			Not Applicable	0.00	3.78										
	Switzerland Lupin Atlantis Holdings SA,	Lupin Management, Inc., USA Lupin Pharma Canada Limited,		Fellow Subsidiary	Any other transaction			Not Applicable	0.00	15.22							-			
248	Switzerland Lupin Atlantis Holdings SA,	Canada		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	193.57	143.70									\vdash
249	Switzerland Lupin Atlantis Holdings SA,	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	0.84	1.30						_			
250	Switzerland Lupin Atlantis Holdings SA,	Lupin Research Inc., USA		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	5.66	11.38									
25:	Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	1.87	5.73									
252	Lupin Atlantis Holdings SA, Switzerland	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00	0.00	5.73									

Rel	ted party transactions for the	period Oct 1, 2022 to Mar	31, 20	023															
													entity/subsidia	ry. These detai			ans, inter-corporate deposits, ad g period when such transaction	vances or investments made or given by was undertaken.	by the listed
	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the	e counte	erparty			Value of the related party		Value of	In case monies are as a result of t		In case any financial indebted loans, inter-corporate depo	iness is incurred to	make or give			-corporate deposits, advances or		
Sr N	/ substant / entering into the transactor			Relationship of the	. , po o o a too part ,	Details of other related	transaction as	Remarks on approval by	transaction during the	us a result or e	ic dansaction	Nature of indebtedness (loan/			Nature (loan/ advance/			Purpose for which the funds will be	Notes
	Name PA	N Name	PAN	counterparty with the listed entity or its subsidiary	transaction	party transaction	approved by the audit	audit committee	reporting period	Opening balance	Closing balance	issuance of debt/ any other etc.)	Details of other indebtedness	Cost Tenure	intercorporate deposit/ investment)	Interest Rate (%)	Tenure Secured/unsecured	utilised by the ultimate recipient of funds (endusage)	
	Lupin Atlantis Holdings SA,			entity of its subsidiary			committee		penou			etc.)			investment)			Tunus (endusage)	
25	Switzerland	Lupin Inc., USA		Fellow Subsidiary	Dividend received			Not Applicable	259.71	0.00	0.00)							
25	Lupin Atlantis Holdings SA, Switzerland	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Interest received			Not Applicable	8.46	0.00	0.00	1							
25	Lupin Atlantis Holdings SA, Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Interest received			Not Applicable	4.90	0.00	0.00								
	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Interest received			Not Applicable	19.49		0.00								
	Lupin Atlantis Holdings SA,																		
	Switzerland Lupin Atlantis Holdings SA,	Lupin Inc., USA Medquimica Industria Farmaceutica		Fellow Subsidiary	Interest received			Not Applicable	24.94		0.00								
25	Switzerland Lupin Atlantis Holdings SA,	LTDA, Brazil		Fellow Subsidiary	Interest received			Not Applicable	13.97	0.00	0.00								
25	Switzerland Lupin Atlantis Holdings SA,	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Any other transaction	Other Income		Not Applicable	16.75	0.00	0.00								
26	Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Any other transaction	Other Income		Not Applicable	6.60	0.00	0.00)							
26	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Any other transaction	Other Income		Not Applicable	2.25	0.00	0.00)							
26	Lupin Atlantis Holdings SA, Switzerland	Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Any other transaction	Other Income		Not Applicable	3.22	0.00	0.00								
	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA		Fellow Subsidiary		Other Income		Not Applicable	0.00		0.00								
	Lupin Atlantis Holdings SA, Switzerland	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	,	• • •		Not Applicable	230.41		0.00								
	Lupin Atlantis Holdings SA,	Lupin Pharma Canada Limited,		· ·	Sale of goods or services														
	Switzerland Lupin Atlantis Holdings SA,	Canada		Fellow Subsidiary	Sale of goods or services			Not Applicable	724.70		0.00								
26	Switzerland Lupin Atlantis Holdings SA,	Lupin Healthcare (UK) Limited, UK Laboratorios Grin, S.A. de C.V.,		Fellow Subsidiary	Sale of goods or services			Not Applicable	173.05	0.00	0.00								
26	Switzerland Lupin Atlantis Holdings SA,	Mexico		Fellow Subsidiary	Loan			Not Applicable	2.58	313.83	316.41				Loan	5.32%	9 yrs Unsecured	Business Purpose	
26	Switzerland	Lupin Healthcare (UK) Limited, UK		Fellow Subsidiary	Loan			Not Applicable	86.80	726.38	813.18	8			Loan	1.25%	2 yrs Unsecured	Business Purpose	
26	Lupin Atlantis Holdings SA, Switzerland	Nanomi B.V., Netherlands		Fellow Subsidiary	Loan			Not Applicable	677.69	982.15	1659.83				Loan	3.75%	3 yrs Unsecured	Business Purpose	
27	Lupin Atlantis Holdings SA, Switzerland	Lupin Inc., USA	7	Fellow Subsidiary	Loan			Not Applicable	23032.35	2440.35	25472.70				Loan		3 yrs Unsecured	Business Purpose	$ \neg$
	Lupin Atlantis Holdings SA, Switzerland	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Loan			Not Applicable	422.59		995.28				Loan		3 yrs Unsecured	Business Purpose	
	Lupin Diagnostics Limited, India	LTDA, BIAZII		renow subsidiary	LOAN			NOT Applicable	422.59	572.09	995.20				LOAN	5.75%	s yrs Unsecured	business Purpose	
27	(formerly known as Lupin Healthcare Limited)	Mr. Nilesh D. Gupta		Key Management Personnel	Any other transaction	Commission / Sitting Fees	0.01	Not Applicable	0.01	0.00	0.00)							
	Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare					Commission / Sitting													
27	Limited) Lupin Diagnostics Limited, India	Mrs. Manju D. Gupta		Non- Executive Directors	Any other transaction	Fees	0.01	Not Applicable	0.01	0.00	0.00								
27	(formerly known as Lupin Healthcare Limited)	Lupin Digital Health Limited, India		Fellow Subsidiary	Sale of goods or services		0.02	Not Applicable	0.02	0.00	0.00								
	Lupin Diagnostics Limited, India	Lupin Digital Health Linited, India			sale of goods of services		0.02	Not Applicable	0.02	0.00	0.00								
27	(formerly known as Lupin Healthcare Limited)	Lupin Digital Health Limited, India		Fellow Subsidiary	Interest paid		0.16	Not Applicable	0.16	0.00	0.00)							
	Lupin Diagnostics Limited, India (formerly known as Lupin Healthcare																		
27	Limited) Lupin Diagnostics Limited, India	Lupin Digital Health Limited, India		Fellow Subsidiary	Any other transaction	Loan Repaid	50.00	Not Applicable	50.00	0.00	0.00								
	(formerly known as Lupin Healthcare Limited)	Lupin Digital Health Limited, India		Fellow Subsidiary	Any other transaction	Loan Taken	50.00	Not Applicable	50.00	0.00	0.00								
21	Lupin Diagnostics Limited, India	cupin Digital Health Limited, India		renow subsidiary	Any other transaction	LUAIT TAKEIT	50.00	NOT Applicable	50.00	0.00	0.00								
27	(formerly known as Lupin Healthcare Limited)	Lupin Digital Health Limited, India		Fellow Subsidiary	Any other transaction	Trade Receivable		Not Applicable	0.00	0.00	0.02	2							
27	Lupin Digital Health Limited, India	Mr. Nilesh D. Gupta		Key Management Personnel		Commission / Sitting Fees		Not Applicable	0.01	0.00	0.00)							
	Lupin Digital Health Limited, India	Mr. Ramesh Swaminathan				Commission / Sitting Fees		Not Applicable	0.01		0.00								
					,	1663													
	Lupin Inc., USA	Lupin Pharmaceuticals, Inc., USA Lupin Pharma Canada Limited,		Fellow Subsidiary	Sale of goods or services			Not Applicable	12756.75		0.00								
28	Lupin Inc., USA	Canada		Fellow Subsidiary	Sale of goods or services			Not Applicable	6.67	0.00	0.00								+
28	Lupin Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	50.40	0.00	0.00								
28	Lupin Inc., USA	Lupin Management, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	31.19	0.00	0.00								
28	Lupin Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	37.37	0.00	0.00								
28	Lupin Inc., USA	Lupin Research Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	16.47	0.00	0.00								
						Expenses incurred on													
28	Lupin Inc., USA	Lupin Oncology Inc., USA		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	0.95	0.00	0.00								
	Lupin Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary		Expenses incurred on their behalf recovered		Not Applicable	83.28	0.00	0.00								
28	capiti itto, UJA	copin rinamiditeuticais, IRC., USA		r cnow publikity				war whhiirable	63.28	0.00	0.00								
28	Lupin Inc., USA	Lupin Research Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	31.10	0.00	0.00								
						Expenses incurred on													
29	Lupin Inc., USA	Lupin Management, Inc., USA		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	29.16	0.00	0.00								
Ι.	1 and a large 1074	No. of Laboratory in 1997		E Han E da Ma		Expenses incurred on				_									
29	Lupin Inc., USA Lupin Inc., USA	Novel Laboratories, Inc., USA Lupin Research Inc., USA		Fellow Subsidiary Fellow Subsidiary	Any other transaction Loan	their behalf recovered		Not Applicable Not Applicable	47.46 0.00		0.00								
29	Lupin Inc., USA	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	7.23	2.86								
29	Lupin Inc., USA Lupin Inc., USA	Lupin Oncology Inc., USA Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable		14.33		7							
29	Lupin Inc., USA	Lupin Research Inc., USA		Fellow Subsidiary	Any other transaction Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	153.89	312.77	1							
	Lupin Inc., USA Lupin Inc., USA	Novel Laboratories, Inc., USA Lupin Management, Inc., USA	_		Any other transaction Any other transaction			Not Applicable Not Applicable	0.00		0.00								
29	Lupin Inc., USA	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	0.00	0.00								
30	Lupin Inc., USA	Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA		Fellow Subsidiary	Any other transaction Any other transaction	TRADE PAYABLES		Not Applicable Not Applicable	0.00	20809.87		8							
30	Lupin Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	1414.60	1776.00)							
30	Lupin Inc., USA	Lupin Management, Inc., USA		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	0.00	0.00								1

Rela	ted party transactions for the	period Oct 1, 2022 to Mar	31, 20	023																
													entity/subsidiar	y. These d	letails need to be disclosed only once	saction relates to lo , during the reportin	ans, inter ng period	r-corporate deposits, adv when such transaction v	ances or investments made or given by vas undertaken.	y the listed
	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the	e count	erparty			Value of the related party	Remarks on	Value of transaction	as a result of th		In case any financial indebted loans, inter-corporate depo				ils of the loans, inter	r-corpora	te deposits, advances or	investments	
Sr No.	Name PA	N Name	PAN	Relationship of the counterparty with the listed	Type of related party transaction	Details of other related party transaction	transaction as approved by	approval by audit committee	during the reporting	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other	Details of other	Cost Te	Nature (loan/ advance/ intercorporate deposit/	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of	Notes
				entity or its subsidiary			the audit committee		period			etc.)	indebtedness		investment)				funds (endusage)	
304	Lupin Inc., USA	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	0.00	2.75									
305	Lupin Management, Inc., USA	Ms.Vinita Gupta		Key Management Personnel	Remuneration		56.54	Approved	56.54	0.00	0.00									
306	Lupin Management, Inc., USA	Generic Health Pty Limited, Australia Laboratorios Grin, S.A. de C.V.,		Fellow Subsidiary	Sale of goods or services			Not Applicable	4.97	0.00	0.00									
307	Lupin Management, Inc., USA	Mexico		Fellow Subsidiary	Sale of goods or services			Not Applicable	22.30	0.00	0.00									
308	Lupin Management, Inc., USA	Lupin Oncology Inc., USA Lupin Pharma Canada Limited,		Fellow Subsidiary	Sale of goods or services			Not Applicable	6.70	0.00	0.00									
309	Lupin Management, Inc., USA	Canada Medquimica Industria Farmaceutica		Fellow Subsidiary	Sale of goods or services			Not Applicable	3.97	0.00	0.00									
310	Lupin Management, Inc., USA	LTDA, Brazil Multicare Pharmaceuticals		Fellow Subsidiary	Sale of goods or services			Not Applicable	19.28	0.00	0.00									
311	Lupin Management, Inc., USA	Philippines, Inc., Philippines		Fellow Subsidiary	Sale of goods or services			Not Applicable	11.90	0.00	0.00									
312	Lupin Management, Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	12.68	0.00	0.00									
	Lupin Management, Inc., USA	Lupin Research Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	10.38	0.00	0.00									
	Lupin Management, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	21.28	0.00	0.00						-			
315	Lupin Management, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	88.32	0.00	0.00									
316	Lupin Management, Inc., USA	Generic Health Pty Limited, Australia		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.64	0.00	0.00									
	Lunin Management Inc. 1774	Constic Hashib Division of American		Follow Subridian	Any other trans	Expenses incurred on		Not Applicable			0									
317	Lupin Management, Inc., USA	Generic Health Pty Limited, Australia Laboratorios Grin, S.A. de C.V.,		Fellow Subsidiary	Any other transaction	their behalf recovered Expenses incurred on		Not Applicable	0.00	0.00	0.00									
318	Lupin Management, Inc., USA	Mexico		Fellow Subsidiary	Any other transaction			Not Applicable	4.52	0.00	0.00									
319	Lupin Management, Inc., USA	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary		Expenses incurred on their behalf recovered		Not Applicable	0.00	0.00	0.00									
	aspectation and a second second			· · · · · · · · · · · · · · · · · · ·		Expenses incurred on														
320	Lupin Management, Inc., USA	Lupin Oncology Inc., USA		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	0.32	0.00	0.00									
321	Lupin Management, Inc., USA	Lupin Oncology Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.00	0.00	0.00									
		Lupin Pharma Canada Limited,				Expenses incurred on														
322	Lupin Management, Inc., USA	Canada		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	0.47	0.00	0.00									
323	Lupin Management, Inc., USA	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.00	0.00	0.00									
		Medquimica Industria Farmaceutica				Expenses incurred on														
324	Lupin Management, Inc., USA	LTDA, Brazil		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	0.00	0.00	0.00									
325	Lupin Management, Inc., USA	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	4.12	0.00	0.00									
326	Lupin Management, Inc., USA	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.00	0.00	0.00									
520	copin monogenent, inc., osre	Multicare Pharmaceuticals		renow Substanty	any other duringedon	Expenses incurred on		not Applicable	0.00	0.00	0.00									
327	Lupin Management, Inc., USA	Philippines, Inc., Philippines		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	3.43	0.00	0.00									
328	Lupin Management, Inc., USA	Multicare Pharmaceuticals Philippines, Inc., Philippines		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.00	0.00	0.00									
						Expenses incurred on														
329	Lupin Management, Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	16.75	0.00	0.00									
330	Lupin Management, Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.40	0.00	0.00									
	Lunin Management Inc. 1774	Lunin Poroarebles 1154		Follow Subridian	Any other transaction	Expenses incurred on		Not Applicable			0									
331	Lupin Management, Inc., USA	Lupin Research Inc., USA		Fellow Subsidiary	any other transaction	Expenses incurred on		Not Applicable	0.92	0.00	0.00									
332	Lupin Management, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Any other transaction			Not Applicable	1.29	0.00	0.00									
333	Lupin Management, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.55	0.00	0.00									
						Expenses incurred on														
334	Lupin Management, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	6.27	0.00	0.00									
335	Lupin Management, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	0.35	0.00	0.00									
336	Lupin Management, Inc., USA	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	10.08	13.72									
337	Lupin Management, Inc., USA	Multicare Pharmaceuticals Philippines, Inc., Philippines		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	8.40	7.85									
338	Lupin Management, Inc., USA	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	9.96	16.89									
339	Lupin Management, Inc., USA	Generic Health Pty Limited, Australia Lupin Pharma Canada Limited,		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	2.00	3.84									
	Lupin Management, Inc., USA Lupin Management, Inc., USA	Lupin Pharma Canada Limited, Canada Lupin Research Inc., USA		Fellow Subsidiary Fellow Subsidiary	Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable	0.00	2.42										
342	Lupin Management, Inc., USA Lupin Management, Inc., USA Lupin Management, Inc., USA	Novel Laboratories, Inc., USA Lupin Inc., USA		Fellow Subsidiary	Any other transaction Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable	0.00	2.65 11.82 0.00	14.68									
344	Lupin Management, Inc., USA Lupin Management, Inc., USA	Lupin Pharmaceuticals, Inc., USA Lupin Oncology Inc., USA		Fellow Subsidiary Fellow Subsidiary Fellow Subsidiary	Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable	0.00	5.09	0.11									
	Lupin Management, Inc., USA	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Any other transaction			Not Applicable	0.00	0.00	0.00									
347	Lupin Management, Inc., USA Lupin Management, Inc., USA	Lupin Pharmaceuticals, Inc., USA Lupin Research Inc., USA			Any other transaction Any other transaction	TRADE PAYABLES		Not Applicable Not Applicable	0.00	0.00	0.00									
	Lupin Management, Inc., USA	Lupin Inc., USA			Any other transaction			Not Applicable	0.00	13.83										

Delet	d party transations for t	he period Oct 1, 2022 to the	21 2	022																
Relat	eu party transactions for th	he period Oct 1, 2022 to Mar	31, 2	023								Additional disclosure of relate							ances or investments made or given by	the listed
	Details of the party (listed entity	Details of the	e court	ternarty			Value of the		Value of			In case any financial indebted	iness is incurred to	make or give	Is need to be disclosed only once			when such transaction v te deposits, advances or		
	/subsidiary) entering into the transact	tion			Type of related party	Details of other related	related party transaction as	Remarks on	transaction	as a result of t	he transaction	loans, inter-corporate depo	osits, advances or in	nvestments		ans of the loans, inter	-corpora	te deposits, advances or		
Sr No.		PAN Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	transaction	party transaction	approved by the audit committee	approval by audit committee	during the reporting period	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
	Lupin Pharma Canada Limited, Canada	Laboratorios Grin, S.A. de C.V., Mexico		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	0.00	0.54									
351	upin Pharmaceuticals, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	37.80	0.00	0.00									
	upin Pharmaceuticals, Inc., USA	Lupin Pharma Canada Limited, Canada		Fellow Subsidiary	Sale of goods or services			Not Applicable	0.41											
		Lupin Research Inc., USA																		
	upin Pharmaceuticals, Inc., USA			Fellow Subsidiary	Sale of goods or services			Not Applicable	2.57											
	upin Pharmaceuticals, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Sale of goods or services			Not Applicable	9.46	0.00	0.00									
355	upin Pharmaceuticals, Inc., USA	Lupin Inc., USA	-	Fellow Subsidiary	Sale of goods or services			Not Applicable	43.51	0.00	0.00									
	upin Pharmaceuticals, Inc., USA upin Pharmaceuticals, Inc., USA	Lupin Management, Inc., USA Lupin Inc., USA	-	Fellow Subsidiary Fellow Subsidiary	Sale of goods or services Any other transaction			Not Applicable Not Applicable	8.37											
		Lupin Pharma Canada Limited,			,	Expenses incurred on														
358	upin Pharmaceuticals, Inc., USA	Canada		Fellow Subsidiary	Any other transaction	their behalf recovered		Not Applicable	2.29	0.00	0.00									
						Expenses incurred on														
359	upin Pharmaceuticals, Inc., USA	Lupin Research Inc., USA	-	Fellow Subsidiary	Any other transaction			Not Applicable	22.56	0.00	0.00									
360	upin Pharmaceuticals, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	93.08	0.00	0.00									
361	upin Pharmaceuticals, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	171.18	0.00	0.00									
						Expenses incurred on														
362	upin Pharmaceuticals, Inc., USA	Lupin Management, Inc., USA Lupin Pharma Canada Limited,	_	Fellow Subsidiary	Any other transaction			Not Applicable	13.11	0.00	0.00									
	upin Pharmaceuticals, Inc., USA upin Pharmaceuticals, Inc., USA	Canada Lupin Research Inc., USA	_	Fellow Subsidiary Fellow Subsidiary	Any other transaction Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable	0.00											
	Lupin Pharmaceuticals, Inc., USA Lupin Pharmaceuticals, Inc., USA	Lupin Research Inc., USA Lupin Inc., USA		Fellow Subsidiary Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable Not Applicable	0.00											
366	upin Pharmaceuticals, Inc., USA	Novel Laboratories, Inc., USA		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	0.62	1.05									
	upin Pharmaceuticals, Inc., USA	Lupin Management, Inc., USA Multicare Pharmaceuticals		Fellow Subsidiary	Any other transaction			Not Applicable	0.00											
	upin Philippines, Inc., Philippines	Philippines, Inc., Philippines Multicare Pharmaceuticals	-	Fellow Subsidiary		Receivables		Not Applicable	0.00											
369	upin Philippines, Inc., Philippines	Philippines, Inc., Philippines Multicare Pharmaceuticals	-	Fellow Subsidiary	Any other transaction	Payables		Not Applicable	0.00											
370	upin Philippines, Inc., Philippines	Philippines, Inc., Philippines Multicare Pharmaceuticals	-	Fellow Subsidiary	Sale of goods or services Purchase of goods or			Not Applicable	0.35	0.00	0.00									
371	upin Philippines, Inc., Philippines	Philippines, Inc., Philippines	-	Fellow Subsidiary	services			Not Applicable	156.92	0.00	0.00									
	upin Research Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Sale of goods or services	DASS TUDOUS		Not Applicable	722.52											
	upin Research Inc., USA upin Research Inc., USA	Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary Fellow Subsidiary	Any other transaction Any other transaction			Not Applicable Not Applicable	117.27 0.00							-				
375	upin Research Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	TRADE PAYABLES		Not Applicable	0.00	153.89	312.77									
	upin Research Inc., USA Multicare Pharmaceuticals	Lupin Management, Inc., USA Laboratorios Grin, S.A. de C.V.,	-	Fellow Subsidiary	Any other transaction	I KADE PAYABLES		Not Applicable	0.00	2.65	6.94					-				
	Philippines, Inc., Philippines	Mexico	_	Fellow Subsidiary	Any other transaction	Receivables		Not Applicable	0.00	0.00	1.39									
378	Nanomi B.V., Netherlands	Generic Health Pty Limited, Australia		Fellow Subsidiary	Investment			Not Applicable	0.00	1188.67	1188.67									
379	Nanomi B.V., Netherlands	Hormosan Pharma GmbH, Germany		Fellow Subsidiary	Investment			Not Applicable	0.00	1207.73	310.74									
380	Nanomi B.V., Netherlands	Pharma Dynamics (Proprietary) Limited, South Africa		Fellow Subsidiary	Investment			Not Applicable	0.00	6878.78	6878.78									
381	Nanomi B.V., Netherlands	Multicare Pharmaceuticals Philippines, Inc., Philippines		Fellow Subsidiary	Investment			Not Applicable	0.00	250.56	250.56									
	Nanomi B.V., Netherlands	Lupin Mexico S.A. de C.V., Mexico		Fellow Subsidiary	Investment			Not Applicable	0.00											
	Nanomi B.V., Netherlands	Lupin Philippines, Inc., Philippines		Fellow Subsidiary	Investment			Not Applicable	0.00		59.89									
	Vanomi B.V., Netherlands	Generic Health SDN. BHD., Malaysia		Fellow Subsidiary	Investment			Not Applicable	0.00		9.29									
	Vanomi B.V., Netherlands	Lupin Inc., USA		Fellow Subsidiary	Investment			Not Applicable	0.00											
386	Nanomi B.V., Netherlands	Medquimica Industria Farmaceutica LTDA, Brazil		Fellow Subsidiary	Investment			Not Applicable	0.00	1316.71	893.74									
	Nanomi B.V., Netherlands	Multicare Pharmaceuticals Philippines, Inc., Philippines		Fellow Subsidiary	Dividend received			Not Applicable	125.66											
	No. 1970 No. 1970	Medquimica Industria Farmaceutica		Sellen School Service	Laboration and the			No. And Sector			0.00									
	Nanomi B.V., Netherlands	LTDA, Brazil Medquimica Industria Farmaceutica	-	Fellow Subsidiary	Interest received			Not Applicable	12.75	0.00	0.00									
	Nanomi B.V., Netherlands	LTDA, Brazil		Fellow Subsidiary	Loan			Not Applicable	0.00						Loan	4.00%	3 yrs	Unsecured	Business Purpose	
	Novel Laboratories, Inc., USA	Lupin Inc., USA	-	Fellow Subsidiary	Sale of goods or services			Not Applicable	55.63		0.00									
391	Novel Laboratories, Inc., USA	Lupin Inc., USA	-	Fellow Subsidiary	Sale of goods or services			Not Applicable	2729.86	0.00	0.00									
392	Novel Laboratories, Inc., USA	Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered		Not Applicable	34.78	0.00	0.00									
1						Expenses incurred on														
	Novel Laboratories, Inc., USA Novel Laboratories, Inc., USA	Lupin Inc., USA Lupin Pharmaceuticals, Inc., USA	-	Fellow Subsidiary Fellow Subsidiary	Any other transaction Any other transaction			Not Applicable Not Applicable	75.87											
395	Novel Laboratories, Inc., USA	Lupin Inc., USA		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES		Not Applicable	0.00	1414.60	1776.00									
396 397	Novel Laboratories, Inc., USA Lupin Inc., USA	Lupin Management, Inc., USA Lupin Pharmaceuticals, Inc., USA	-	Fellow Subsidiary Fellow Subsidiary	Any other transaction Investment	TRADE PAYABLES		Not Applicable Not Applicable	0.00											
398	upin Inc., USA upin Inc., USA	Lupin Research Inc., USA Novel Laboratories, Inc., USA		Fellow Subsidiary Fellow Subsidiary	Investment Investment			Not Applicable Not Applicable	0.00							-				
											01/2.5/									
Total va	ue of transaction during the reporting	period							70,967.87											